A new clinical trial listing for IBI3042 appeared on August 28, 2026. The study, titled "IBI3042 Study in Healthy Participants and Overweight or Obese Participants," is registered as a Phase 1 trial. Its current status is not yet recruiting, according to the trial record identified as NCT07793019.
The trial listing does not include details on results, dosing, or timelines beyond its current registration status. As a Phase 1 study, it is an early stage trial, and no outcome data have been reported at this time. The record indicates the study is intended to include both healthy participants and participants who are overweight or obese, though specific enrollment criteria were not provided in this update.
This entry reflects only the registration and status information available as of the listed date. No efficacy, safety, or comparative data have been disclosed in connection with this trial update. Further information may become available as the study progresses toward recruitment and beyond.
Readers interested in background on calcitonin, the compound associated with this listing, can consult the compound overview for additional context.